Compare · RMD vs SGHT
RMD vs SGHT
Side-by-side comparison of ResMed Inc. (RMD) and Sight Sciences Inc. (SGHT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both RMD and SGHT operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $28.44B, about 117.4x SGHT ($242.1M).
- Over the past year, RMD is down 22.9% and SGHT is up 12.6% - SGHT leads by 35.5 points.
- SGHT has been more active in the news (8 items in the past 4 weeks vs 6 for RMD).
- RMD has more recent analyst coverage (25 ratings vs 19 for SGHT).
- Company
- ResMed Inc.
- Sight Sciences Inc.
- Price
- $193.65-1.21%
- $4.57+2.24%
- Market cap
- $28.44B
- $242.1M
- 1M return
- -6.35%
- -13.45%
- 1Y return
- -22.89%
- +12.56%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 6
- 8
- Recent ratings
- 25
- 19
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Sight Sciences Inc.
Sight Sciences, Inc., an ophthalmic medical device company, engages the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology, for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.
Latest RMD
- Global General Counsel Rider Michael J covered exercise/tax liability with 269 units of ResMed Common Stock, decreasing direct ownership by 3% to 9,488 units (SEC Form 4) (tax withholding)
- Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million
- Resmed Completes Acquisition of Noctrix Health, Expanding Clinical Sleep Health Portfolio
- SEC Form SD filed by ResMed Inc.
- Resmed Announces Participation in the 46th Annual William Blair Growth Stock Conference
- Resmed and ŌURA Partner to Expand Access to Sleep Health Education and Care
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,037,233 worth of ResMed Common Stock (4,991 units at $207.82) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 3 filed by new insider Bloomer Aaron
- SEC Form 4 filed by Chief Financial Officer Sandercock Brett
- SEC Form 8-K filed by ResMed Inc.
Latest SGHT
- Director Fountain Tamara was granted 28,261 shares, increasing direct ownership by 35% to 109,650 units (SEC Form 4)
- Director Encrantz Staffan was granted 28,261 shares, increasing direct ownership by 2% to 1,420,183 units (SEC Form 4)
- Director Burbach Gerhard F was granted 28,261 shares, increasing direct ownership by 30% to 123,207 units (SEC Form 4)
- Director Zurbay Donald was granted 28,261 shares, increasing direct ownership by 17% to 193,613 units (SEC Form 4)
- Director Mazzacco Catherine was granted 28,261 shares, increasing direct ownership by 69% to 69,276 units (SEC Form 4)
- Sight Sciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form SD filed by Sight Sciences Inc.
- Chief Operating Officer Bauerlein Alison sold $65,167 worth of shares (12,728 units at $5.12), decreasing direct ownership by 2% to 688,893 units (SEC Form 4)
- SEC Form 10-Q filed by Sight Sciences Inc.
- Sight Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits